Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On February 23, 2024, we issued a total of 986,299 shares of our Class A common stock to certain former equity holders of Altar SAS, valued at approximately $1.4 million, in connection with achievement of a certain milestone, in a private placement transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act.
On February 23, 2024, we issued a total of 1,832,172 shares of our Class A common stock to Reverie Labs, Inc. (“Reverie”), valued at approximately $2.4 million, as consideration in connection with the acquisition of certain infrastructure and software assets from Reverie, in a private placement transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act.
On March 7 and March 26, 2024, we issued 11,179,115 and 121,557 shares of our Class A common stock, respectively, to certain sellers of Patch Biosciences, Inc. (“Patch”), valued at approximately $14.4 million, as consideration in connection with the acquisition by merger of Patch, in a private placement transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
37
Table of Contents
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.